ClinicalTrials.gg
RecruitingNCT07680764Updated Oct 23, 2026

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pumitamig and Imzokitug in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) and Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Recruiting at 74 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 23, 2026Start date movedInterventions changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 13 under way, 3 of them phase 3. pumitamig · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
9th of 13
160 · median 594
Started
2026
with 4 others
Phase 2
5 of 13
5 open now
Primary completion
2028-09
later than 2 of 12 live
Registered
12th of 13
by date
Lead sponsor
5 of 13
Bristol-Myers Squibb

Among the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by planned enrollment, is one of 5 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pumitamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

03

Conditions studied

  • Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer (NSCLC)

Keywords

  • Squamous Non-Small Cell Lung Cancer (NSCLC)
  • Non-squamous Non-Small Cell Lung Cancer (NSCLC)
  • Immunotherapy
  • Bispecific antibody
  • Imzokitug
  • Anti-CCR8 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
  • Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or disease.
  • Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of ) for each participant must be submitted by the site.
  • Participants must have an Performance Status of 0 or 1.
  • Participants must have per (RECIST) v1.1.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any documented actionable genomic alterations (AGAs) for which approved targeted therapies are indicated.
  • Participants must not have prior treatment with immuno-oncology therapies.
  • Participants must not have untreated central nervous system (CNS) .
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Arm A: Pumitamig + Imzokitug + Histology-based PDCT

    Drug: Pumitamig · Drug: Imzokitug · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Arm B: Pumitamig + Imzokitug + Histology-based PDCT

    Drug: Pumitamig · Drug: Imzokitug · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Arm C: Pumitamig + Imzokitug + Histology-based PDCT

    Drug: Pumitamig · Drug: Imzokitug · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Arm D: Pumitamig + Histology-based PDCT

    Drug: Pumitamig · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • Specified dose on specified days

    Also known as: BMS-986545, BNT327, PM8002

  • Specified dose on specified days

    Also known as: Anti-CCR8, BMS-986340

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 90 days after discontinuation of study treatment

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 90 days after discontinuation of study treatment

  3. Number of participants with treatment-related AEs

    Time frame: Up to 90 days after discontinuation of study treatment

  4. Number of participants with treatment-related SAEs

    Time frame: Up to 90 days after discontinuation of study treatment

  5. Number of participants with AEs leading to discontinuation

    Time frame: Up to 90 days after discontinuation of study treatment

  6. Number of deaths

    Time frame: Up to 90 days after discontinuation of study treatment

  7. Progression free survival (PFS) by investigator (per RECIST v1.1)

    Time frame: Up to approximately 4 years

  8. Overall survival (OS)

    Time frame: Up to approximately 4 years

  9. Duration of response (DOR) by investigator (per RECIST v1.1)

    Time frame: Up to approximately 4 years

  10. Time to recurrence (TTR) by investigator (per RECIST v1.1)

    Time frame: Up to approximately 4 years

07

Study locations

33 of 74 sites recruiting
  • Local Institution - 0183
    Washington D.C., District of Columbia 20016, United States
    Not yet recruiting
    • Site 0183 · Contact
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
    Recruiting
    • Frederick Flynt Jr, Site 0170 · Contact402-334-4773
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
    Recruiting
    • Firas Badin, Site 0034 · Contact859-276-0414
  • Baptist Health Hamburg
    Lexington, Kentucky 40509, United States
    Recruiting
    • Firas Badin, Site 0171 · Contact859-260-6100
  • Local Institution - 0123
    Baltimore, Maryland 21224, United States
    Not yet recruiting
    • Site 0123 · Contact
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
    Recruiting
    • John Hrom, Site 0180 · Contact601-261-1700
  • Nebraska Cancer Specialists
    Grand Island, Nebraska 68803, United States
    Recruiting
    • Joel Michalski, Site 0172 · Contact402-955-2691
  • Oncology Hematology West PC
    Omaha, Nebraska 68130, United States
    Recruiting
    • Joel Michalski, Site 0102 · Contact402-955-2691
  • Local Institution - 0080
    New York, New York 10021, United States
    Not yet recruiting
    • Site 0080 · Contact
  • Local Institution - 0176
    Columbus, Ohio 43210, United States
    Not yet recruiting
    • Site 0176 · Contact
  • Local Institution - 0095
    Houston, Texas 77030, United States
    Not yet recruiting
    • Site 0095 · Contact
  • Local Institution - 0135
    Madison, Wisconsin 53792, United States
    Not yet recruiting
    • Site 0135 · Contact
  • Sanatorio Parque Rosario
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
    • Gaston Martinengo, Site 0082 · Contact5493416955611
  • Instituto Medico Especializado Alexander Fleming
    Buenos Aires, C1426ANZ, Argentina
    Recruiting
    • Claudio Martin, Site 0094 · Contact5491166936669
  • Clinica Viedma S.A.
    Viedma, R8500ACE, Argentina
    Recruiting
    • Ruben Kowalyszyn, Site 0092 · Contact5492920601693
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
    Recruiting
    • Matthew Chan, Site 0074 · Contact
  • Local Institution - 0134
    Westmead, New South Wales 2145, Australia
    Not yet recruiting
    • Site 0134 · Contact
  • Local Institution - 0167
    Greenslopes, Queensland 4120, Australia
    Not yet recruiting
    • Site 0167 · Contact
  • Local Institution - 0100
    Heidelberg, Victoria 3084, Australia
    Not yet recruiting
    • Site 0100 · Contact
  • St. John of God Murdoch Hospital
    Perth, Western Australia 6150, Australia
    Recruiting
    • Kynan Feeney, Site 0048 · Contact+61894389599
  • Local Institution - 0003
    Natal/RN, Rio Grande do Norte 59062-000, Brazil
    Not yet recruiting
    • Site 0003 · Contact
  • Local Institution - 0006
    Porto Alegre, Rio Grande do Sul 91610-000, Brazil
    Not yet recruiting
    • Site 0006 · Contact
  • Local Institution - 0005
    Barretos, São Paulo 14784, Brazil
    Not yet recruiting
    • Site 0005 · Contact
  • Local Institution - 0001
    São Paulo, 01246-000, Brazil
    Not yet recruiting
    • Site 0001 · Contact
  • Orlandi Oncologia
    Santiago, Santiago Metropolitan 7500713, Chile
    Recruiting
    • Francisco Orlandi, Site 0081 · Contact56992214787
  • Bradfordhill
    Santiago, Santiago Metropolitan 8420383, Chile
    Recruiting
    • Carlos Rojas, Site 0149 · Contact+56998744662
  • Oncocentro Apys
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Alejandro Acevedo Gaete, Site 0084 · Contact+56992369820
  • Local Institution - 0038
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
    • Site 0038 · Contact
  • Local Institution - 0138
    Fuzhou, Fujian 350014, China
    Not yet recruiting
    • Site 0138 · Contact
  • Local Institution - 0050
    Wuhan, Hubei 430030, China
    Not yet recruiting
    • Site 0050 · Contact
  • Local Institution - 0147
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Site 0147 · Contact
  • Local Institution - 0140
    Shanghai, Shanghai Municipality 200030, China
    Not yet recruiting
    • Site 0140 · Contact
  • Local Institution - 0169
    Shanghai, Shanghai Municipality 200032, China
    Not yet recruiting
    • Site 0169 · Contact
  • Local Institution - 0144
    Chengdu, Sichuan 610213, China
    Not yet recruiting
    • Site 0144 · Contact
  • Local Institution - 0137
    Hangzhou, Zhejiang 310016, China
    Not yet recruiting
    • Site 0137 · Contact
  • Local Institution - 0131
    Nice, Alpes-Maritimes 6100, France
    Not yet recruiting
    • Site 0131 · Contact
  • Hôpital Arnaud de Villeneuve - CHU Montpellier
    Montpellier, Hérault 34090, France
    Recruiting
    • Benoit Roch, Site 0117 · Contact+33467330759
  • Local Institution - 0087
    Montpellier, Languedoc-Roussillon 34070, France
    Not yet recruiting
    • Site 0087 · Contact
  • Local Institution - 0119
    Villejuif, Val-de-Marne 94800, France
    Not yet recruiting
    • Site 0119 · Contact
  • Local Institution - 0047
    Grenoble, 38043 Cedex 09, France
    Not yet recruiting
    • Site 0047 · Contact
  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord
    Marseille, 13915, France
    Recruiting
    • Laurent Greillier, Site 0110 · Contact33491324400
  • Hopitaux Universitaires Paris Centre-Hopital Cochin
    Paris, 75014, France
    Recruiting
    • Marie Wislez, Site 0109 · Contact33158413091
  • Local Institution - 0085
    Saint-Herblain, 44800, France
    Not yet recruiting
    • Site 0085 · Contact
  • Local Institution - 0019
    Paris, Île-de-France Region 75005, France
    Not yet recruiting
    • Site 0019 · Contact
  • Robert Bosch Krankenhaus
    Stuttgart, Baden-Wurttemberg 70376, Germany
    Recruiting
    • Martin Kimmich, Site 0126 · Contact4971181017719
  • Local Institution - 0156
    Marburg, Hesse 35043, Germany
    Not yet recruiting
    • Site 0156 · Contact
  • Local Institution - 0152
    Homburg, Saarland 66424, Germany
    Not yet recruiting
    • Site 0152 · Contact
  • Klinikum Köln-Merheim
    Cologne, 51109, Germany
    Recruiting
    • Eva-Lotte Buchmeier, Site 0065 · Contact+49221890713962
  • Christliches Klinikum Halle (Saale) GmbH
    Halle, 06120, Germany
    Recruiting
    • Miriam Moeller, Site 0042 · Contact00493455591440
  • Universitatsklinikum Frankfurt
    Hessen, 60590, Germany
    Recruiting
    • Friederike Althoff, Site 0125 · Contact
  • Local Institution - 0148
    Bergamo, BG 24127, Italy
    Not yet recruiting
    • Site 0148 · Contact
  • Humanitas Istituto Clinico Catanese
    Misterbianco, Catania 95045, Italy
    Recruiting
    • Alessandro Russo, Site 0128 · Contact393280569761
  • Local Institution - 0043
    Bari, 70124, Italy
    Not yet recruiting
    • Site 0043 · Contact
  • Local Institution - 0159
    Milan, 20142, Italy
    Not yet recruiting
    • Site 0159 · Contact
  • Local Institution - 0014
    Ravenna, 48121, Italy
    Not yet recruiting
    • Site 0014 · Contact
  • Local Institution - 0011
    Rozzano (MI), 20089, Italy
    Not yet recruiting
    • Site 0011 · Contact
  • Amethyst Radiotherapy Center-Oncologie Medicala
    Florești, Cluj 407280, Romania
    Recruiting
    • Andrei Ungureanu, Site 0114 · Contact40742206212
  • Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti (IOB)
    Bucharest, 022328, Romania
    Recruiting
    • Aurelia Alexandru, Site 0076 · Contact40723289606
  • Institutul Oncologic Cluj
    Cluj-Napoca, 400015, Romania
    Recruiting
    • Tudor Ciuleanu, Site 0008 · Contact40745646368
  • Centrul de Oncologie Sf. Nectarie SRL
    Craiova, 200347, Romania
    Recruiting
    • Michael Schenker, Site 0075 · Contact40727774974
  • Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)
    Iași, 700106, Romania
    Recruiting
    • Constantin Volovat, Site 0115 · Contact40746110096
  • Institutul Regional de Oncologie Iasi
    Iași, 700483, Romania
    Recruiting
    • Dana Clement, Site 0116 · Contact40744692062
  • Oncohelp
    Timisoara, Timis, 300239, Romania
    Recruiting
    • Daniela Sirbu, Site 0113 · Contact40744571617
  • Local Institution - 0132
    Badalona, Barcelona 8916, Spain
    Not yet recruiting
    • Site 0132 · Contact
  • Local Institution - 0162
    Seville, Seville 41013, Spain
    Not yet recruiting
    • Site 0162 · Contact
  • Hospital Universitari Vall D'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Enriqueta Felip Font, Site 0027 · Contact34932746077
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
    Recruiting
    • Margarita Majem Tarruella, Site 0068 · Contact34935565651
  • Local Institution - 0163
    Barcelona, 8036, Spain
    Not yet recruiting
    • Site 0163 · Contact
  • Local Institution - 0041
    Madrid, 28041, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0010
    Majadahonda, 28222, Spain
    Not yet recruiting
    • Site 0010 · Contact
  • Hospital Carlos Haya De Malaga
    Málaga, 29010, Spain
    Recruiting
    • Manuel Cobo-Dols, Site 0020 · Contact00349422033350000
  • Local Institution - 0182
    Birmingham, BIR B9 5SS, United Kingdom
    Not yet recruiting
    • Site 0182 · Contact
  • Local Institution - 0035
    London, Greater London SE19RT, United Kingdom
    Not yet recruiting
    • Site 0035 · Contact
  • The Royal Surrey County Hospital NHS Foundation Trust
    Guildford, GU2 7XX, United Kingdom
    Recruiting
    • Ali Suwaidan, Site 0037 · Contact01483571122
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Sep 10, 2026was Aug 2026
Primary completionEst.
Sep 15, 2028
CompletionEst.
Sep 15, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
36 sites added, 33 sites removed
Show 36 added (7 Romania, 6 United States, 5 Germany, 3 Argentina, 3 France, 3 Spain, 3 Chile, 2 Australia, 2 United Kingdom, 2 Italy)
  • Local Institution - 0183 · Washington D.C., United States
  • University Cancer & Blood Center, LLC · Athens, United States
  • Local Institution - 0176 · Columbus, United States
  • Sanatorio Parque Rosario · Rosario, Argentina
  • Instituto Medico Especializado Alexander Fleming · Buenos Aires, Argentina
  • Clinica Viedma S.A. · Viedma, Argentina
  • St. John of God Murdoch Hospital · Perth, Australia
  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord · Marseille, France
  • Robert Bosch Krankenhaus · Stuttgart, Germany
  • Christliches Klinikum Halle (Saale) GmbH · Haile, Germany
  • Institutul Oncologic Cluj · Cluj-Napoca, Romania
  • Centrul de Oncologie Sf. Nectarie SRL · Craiova, Romania
  • Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center) · Iași, Romania
  • Institutul Regional de Oncologie Iasi · Iași, Romania
  • Hospital Carlos Haya De Malaga · Málaga, Spain
  • Local Institution - 0182 · Birmingham, United Kingdom
  • The Royal Surrey County Hospital NHS Foundation Trust · Guildford, United Kingdom
  • Baptist Health Lexington · Lexington, United States
  • Baptist Health Hamburg · Lexington, United States
  • Hattiesburg Clinic · Hattiesburg, United States
  • Gosford Hospital · Gosford, Australia
  • Orlandi Oncologia · Santiago, Chile
  • Bradfordhill · Santiago, Chile
  • Oncocentro Apys · Viña del Mar, Chile
  • Hôpital Arnaud de Villeneuve - CHU Montpellier · Montpellier, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin · Paris, France
  • Klinikum Köln-Merheim · Cologne, Germany
  • Christliches Klinikum Halle (Saale) GmbH · Halle, Germany
  • Universitatsklinikum Frankfurt · Hessen, Germany
  • Local Institution - 0148 · Bergamo, Italy
  • …and 6 more on the registry record
Show 33 removed
  • Local Institution - 0170 · Athens, United States
  • Local Institution - 0082 · Rosario, Argentina
  • Local Institution - 0094 · Buenos Aires, Argentina
  • Local Institution - 0092 · Viedma, Argentina
  • Local Institution - 0048 · Perth, Australia
  • Local Institution - 0110 · Marseille, France
  • Local Institution - 0126 · Stuttgart, Germany
  • Local Institution - 0042 · Haile, Germany
  • Local Institution - 0008 · Cluj-Napoca, Romania
  • Local Institution - 0075 · Craiova, Romania
  • Local Institution - 0115 · Iași, Romania
  • Local Institution - 0116 · Iași, Romania
  • Local Institution - 0020 · Málaga, Spain
  • Local Institution - 0182 · Birmingham, United Kingdom
  • Local Institution - 0037 · Guildford, United Kingdom
  • Local Institution - 0034 · Lexington, United States
  • Local Institution - 0171 · Lexington, United States
  • Local Institution - 0180 · Hattiesburg, United States
  • Local Institution - 0074 · Gosford, Australia
  • Local Institution - 0081 · Santiago, Chile
  • Local Institution - 0149 · Santiago, Chile
  • Local Institution - 0084 · Viña del Mar, Chile
  • Local Institution - 0109 · Paris, France
  • Local Institution - 0065 · Cologne, Germany
  • Christliches Klinikum Halle (Saale) GmbH · Haile, Germany
  • Local Institution - 0125 · Hessen, Germany
  • Local Institution - 0128 · Misterbianco, Italy
  • Local Institution - 0148 · Bergamo, Italy
  • Local Institution - 0114 · Florești, Romania
  • Local Institution - 0113 · Timișoara, Romania
  • …and 3 more on the registry record
across 2 updates, Oct 2, 2026 – Oct 23, 2026
Start date
Aug 31, 2026→Sep 10, 2026 (actual)
Oct 2, 2026
Interventions
Removed Drug: Infliximab·Drug: Vedolizumab
Oct 2, 2026
Show all 2 updates
  1. Oct 23, 2026
    19 sites added, 18 sites removed
    Show 19 added (3 United States, 3 Chile, 3 Germany, 3 Romania, 2 France, 2 Italy, 2 Spain, 1 Australia)
    • Baptist Health Lexington · Lexington, United States
    • Baptist Health Hamburg · Lexington, United States
    • Hattiesburg Clinic · Hattiesburg, United States
    • Gosford Hospital · Gosford, Australia
    • Orlandi Oncologia · Santiago, Chile
    • Bradfordhill · Santiago, Chile
    • Oncocentro Apys · Viña del Mar, Chile
    • Hôpital Arnaud de Villeneuve - CHU Montpellier · Montpellier, France
    • Hopitaux Universitaires Paris Centre-Hopital Cochin · Paris, France
    • Klinikum Köln-Merheim · Cologne, Germany
    • Christliches Klinikum Halle (Saale) GmbH · Halle, Germany
    • Universitatsklinikum Frankfurt · Hessen, Germany
    • Local Institution - 0148 · Bergamo, Italy
    • Humanitas Istituto Clinico Catanese · Misterbianco, Italy
    • Amethyst Radiotherapy Center-Oncologie Medicala · Florești, Romania
    • Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti (IOB) · Bucharest, Romania
    • Oncohelp · Timisoara, Timis, Romania
    • Hospital Universitari Vall D'Hebron · Barcelona, Spain
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    Show 18 removed
    • Local Institution - 0034 · Lexington, United States
    • Local Institution - 0171 · Lexington, United States
    • Local Institution - 0180 · Hattiesburg, United States
    • Local Institution - 0074 · Gosford, Australia
    • Local Institution - 0081 · Santiago, Chile
    • Local Institution - 0149 · Santiago, Chile
    • Local Institution - 0084 · Viña del Mar, Chile
    • Local Institution - 0109 · Paris, France
    • Local Institution - 0065 · Cologne, Germany
    • Christliches Klinikum Halle (Saale) GmbH · Haile, Germany
    • Local Institution - 0125 · Hessen, Germany
    • Local Institution - 0128 · Misterbianco, Italy
    • Local Institution - 0148 · Bergamo, Italy
    • Local Institution - 0114 · Florești, Romania
    • Local Institution - 0113 · Timișoara, Romania
    • Local Institution - 0076 · Bucharest, Romania
    • Local Institution - 0027 · Barcelona, Spain
    • Local Institution - 0068 · Barcelona, Spain
    + 1 other change: verification date
  2. Oct 2, 2026
    17 sites added, 15 sites removed
    Show 17 added (4 Romania, 3 United States, 3 Argentina, 2 Germany, 2 United Kingdom, 1 Australia, 1 France, 1 Spain)
    • Local Institution - 0183 · Washington D.C., United States
    • University Cancer & Blood Center, LLC · Athens, United States
    • Local Institution - 0176 · Columbus, United States
    • Sanatorio Parque Rosario · Rosario, Argentina
    • Instituto Medico Especializado Alexander Fleming · Buenos Aires, Argentina
    • Clinica Viedma S.A. · Viedma, Argentina
    • St. John of God Murdoch Hospital · Perth, Australia
    • Assistance Publique Hôpitaux de Marseille - Hôpital Nord · Marseille, France
    • Robert Bosch Krankenhaus · Stuttgart, Germany
    • Christliches Klinikum Halle (Saale) GmbH · Haile, Germany
    • Institutul Oncologic Cluj · Cluj-Napoca, Romania
    • Centrul de Oncologie Sf. Nectarie SRL · Craiova, Romania
    • Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center) · Iași, Romania
    • Institutul Regional de Oncologie Iasi · Iași, Romania
    • Hospital Carlos Haya De Malaga · Málaga, Spain
    • Local Institution - 0182 · Birmingham, United Kingdom
    • The Royal Surrey County Hospital NHS Foundation Trust · Guildford, United Kingdom
    Show 15 removed
    • Local Institution - 0170 · Athens, United States
    • Local Institution - 0082 · Rosario, Argentina
    • Local Institution - 0094 · Buenos Aires, Argentina
    • Local Institution - 0092 · Viedma, Argentina
    • Local Institution - 0048 · Perth, Australia
    • Local Institution - 0110 · Marseille, France
    • Local Institution - 0126 · Stuttgart, Germany
    • Local Institution - 0042 · Haile, Germany
    • Local Institution - 0008 · Cluj-Napoca, Romania
    • Local Institution - 0075 · Craiova, Romania
    • Local Institution - 0115 · Iași, Romania
    • Local Institution - 0116 · Iași, Romania
    • Local Institution - 0020 · Málaga, Spain
    • Local Institution - 0182 · Birmingham, United Kingdom
    • Local Institution - 0037 · Guildford, United Kingdom
    Start date Aug 31, 2026→Sep 10, 2026 (now actual)
    Interventions Removed Drug: Infliximab·Drug: Vedolizumab
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07680764
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Sep 10, 2026
Primary completion
Sep 15, 2028 (estimated)
Completion
Sep 15, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pumitamig · Imzokitug

Start the discussion